resveratrol
stilbenoid
compound
found
numer
plant
resveratrol
investig
potenti
therapeut
effect
variou
diseas
chen
et
al
albani
et
al
sawda
et
al
sun
et
al
singh
et
al
li
et
al
also
shown
potenti
antivir
abba
et
al
lin
et
al
b
antibacteri
activ
pathogen
includ
helicobact
pylori
propionibacterium
acn
staphylococcu
aureu
mahadi
et
al
su
et
al
taylor
et
al
antioxyd
activ
interact
variou
molecular
target
includ
kinas
sirtuin
cytokin
suggest
mechan
respons
resveratrol
activ
although
knowledg
aspect
remain
limit
et
al
polymyxin
old
antibiot
recent
rare
use
clinic
set
except
practic
select
digest
decontamin
sdd
carri
icu
set
reduc
infect
caus
microorgan
oropharyng
gastrointestin
tract
abi
et
al
baryoseph
et
al
rawson
et
al
recent
due
emerg
extrem
drug
resist
xdr
strain
gramneg
pathogen
carbapenemresist
enterobacteriacea
cre
carbapenemresist
acinetobact
sp
cra
polymyxin
regain
major
role
lastresort
agent
infect
consumpt
remark
increas
falaga
kasiak
kay
et
al
unfortun
also
polymyxin
resist
emerg
increasingli
report
especi
among
cre
cra
cannatelli
et
al
monaco
et
al
granata
petrosillo
jeannot
et
al
nowak
et
al
narrow
treatment
option
studi
test
vitro
activ
resveratrol
alon
combin
colistin
collect
colistinresist
colr
gramneg
pathogen
differ
speci
despit
lack
signific
intrins
antimicrobi
activ
resveratrol
exhibit
strong
synergist
effect
colistin
mani
colr
strain
differ
speci
includ
escherichia
coli
klebsiella
pneumonia
enterobact
cloaca
stenotrophomona
maltophilia
citrobact
braakii
also
enterobacteri
speci
natur
resist
polymyxin
eg
proteu
mirabili
serratia
marcescen
bacteri
strain
investig
work
list
tabl
includ
colr
strain
differ
speci
baumannii
k
pneumonia
e
coli
e
cloaca
maltophilia
c
braakii
p
mirabili
marcescen
three
colistinsuscept
col
k
pneumonia
precursor
three
colr
strain
maltophilia
clinic
breakpoint
colistin
avail
definit
colr
arbitrarili
base
highlevel
colistin
mic
ie
mgl
compar
colistin
mic
distribut
speci
sergio
et
al
strain
mechan
colistin
resist
previous
character
tabl
colistin
sulfat
resveratrol
obtain
sigmaaldrich
saint
quentin
fallavi
franc
resveratrol
thermo
fisher
germani
dissolv
dimethyl
sulfoxid
dmso
sigmaaldrich
saint
loui
usa
concentr
mgml
mic
colistin
resveratrol
determin
refer
broth
microdilut
clinic
laboratori
standard
institut
use
cationadjust
muellerhinton
broth
mhb
florenc
itali
colistin
mic
interpret
accordingli
eucast
clinic
breakpoint
version
wwweucastorg
checkerboard
assay
test
antimicrobi
activ
combin
colistin
plu
resveratrol
carri
describ
previous
tascini
et
al
use
mhb
microtit
plate
sarst
germani
well
inocul
suspens
cfuml
test
strain
final
volum
inocula
prepar
direct
suspens
mhb
bacteria
grown
overnight
onto
mh
agar
plate
result
read
incub
h
interpret
follow
fici
synerg
fici
antagon
fici
interact
data
obtain
least
two
independ
experi
assay
perform
duplic
inocul
cfu
strain
ml
mhb
deep
well
rb
block
thermo
fisher
scientif
usa
static
condit
clinic
laboratori
standard
institut
cfu
count
determin
differ
time
point
plate
appropri
dilut
onto
lb
agar
sezonov
et
al
time
kill
assay
dmso
concentr
remain
alway
vv
recommend
clsi
guidelin
clinic
laboratori
standard
institut
mic
test
checkerboard
assay
condit
resveratrol
concentr
mgl
contain
dmso
concentr
higher
ie
respect
appropri
control
exclud
potenti
synergist
activ
colistin
dmso
alway
includ
collect
strain
eight
differ
gramneg
speci
test
suscept
resveratrol
colistin
combin
thereof
collect
includ
colr
strain
speci
natur
suscept
colistin
c
braakii
e
coli
k
pneumonia
e
cloaca
baumannii
two
colr
strain
natur
resist
speci
marcescen
p
mirabili
one
maltophilia
strain
high
colistin
mic
consid
colr
purpos
work
also
includ
three
col
strain
k
pneumonia
precursor
three
colr
strain
tabl
mic
resveratrol
mgl
test
strain
show
lack
intrins
antimicrobi
activ
resveratrol
alon
gramneg
pathogen
checkerboard
assay
reveal
clear
dosedepend
synergist
activ
resveratrol
colistin
vs
colr
strain
differ
speci
includ
intrins
resist
speci
marcescen
p
mirabili
synerg
observ
two
four
colr
e
coli
strain
carri
determin
col
k
pneumonia
precursor
three
colr
strain
tabl
synerg
evid
resveratrol
abl
decreas
colistin
mic
valu
equal
lower
suscept
breakpoint
ie
mgl
case
concentr
variabl
mgl
particular
case
four
six
colr
e
coli
five
six
colr
k
pneumonia
colr
c
braakii
colr
strain
baumanni
e
cloaca
maltophilia
type
strain
marcescen
synergist
effect
observ
presenc
differ
colistin
resist
mechan
strain
differ
clonal
lineag
includ
repres
known
high
risk
clone
eg
e
coli
k
pneumonia
tabl
order
investig
colistin
combin
resveratrol
bactericid
effect
timekil
assay
carri
colr
strain
checkerboard
assay
show
synergist
effect
colistin
concentr
use
timekil
experi
correspond
clinic
breakpoint
suscept
mgl
mic
mic
resveratrol
concentr
use
mgl
abl
inhibit
growth
case
combin
colistin
mgl
tabl
timekil
assay
show
bactericid
activ
ie
reduct
initi
bacteri
inoculum
resveratrol
mgl
combin
colistin
mgl
colr
strain
test
four
strain
e
coli
k
pneumonia
k
pneumonia
baumannii
combin
exert
static
effect
figur
overal
strain
colistin
use
x
mic
x
mic
combin
resveratrol
mgl
bactericid
effect
observ
except
e
coli
combin
seem
less
effect
figur
altogeth
result
consist
data
obtain
checkerboard
assay
tabl
fact
strain
exhibit
colistin
mic
mgl
mgl
combin
resveratrol
mgl
show
bactericid
bacteriostat
effect
timekil
curv
respect
hand
variabl
effect
observ
strain
presenc
resveratrol
mgl
colistin
mic
lower
mgl
figur
consid
divers
speci
test
c
braakii
e
coli
k
pneumonia
e
cloaca
marcescen
baumannii
maltophilia
express
differ
colistin
resist
mechan
cidalstat
activ
colistin
mgl
combin
resveratrol
mgl
appear
depend
speci
resist
mechan
absenc
synergist
activ
col
strain
could
suggest
like
resveratrol
interact
lipid
modif
system
respons
colistin
resist
colr
strain
howev
mechan
synerg
observ
resveratrol
colistin
colr
strain
remain
unknown
subject
investig
mdr
xdr
gramneg
bacteria
eg
cre
cra
increasingli
report
worldwid
cannatelli
et
al
monaco
et
al
list
among
resist
pathogen
highest
prioriti
research
develop
new
antibiot
colistin
remain
one
antibiot
activ
pathogen
repres
drug
last
resort
treatment
cre
cra
sever
infect
falaga
kasiak
kay
et
al
also
use
select
digest
decontamin
sdd
combin
agent
ie
tobramycin
amphotericin
b
abi
et
al
rawson
et
al
increasingli
administ
manag
chronic
lung
colon
pseudomona
aeruginosa
cystic
fibrosi
sherrard
et
al
perspect
increasingli
dissemin
colistin
resist
pathogen
repres
matter
public
health
concern
cannatelli
et
al
monaco
et
al
granata
petrosillo
jeannot
et
al
nowak
et
al
worrisom
scenario
forc
scientif
commun
evalu
new
therapeut
approach
face
antibiot
resist
crisi
one
promis
strategi
offer
nonantibiot
drug
overcom
resist
mechan
antibiot
resist
breaker
arb
combin
fail
antibiot
brown
wellproven
exampl
approach
repres
new
betalactamas
inhibitor
ie
avibactam
vaborbactam
giani
et
al
nonetheless
consid
multitud
resist
determin
rapid
evolut
potenti
addit
solut
must
implement
among
divers
approach
investig
last
year
natur
compound
ie
resveratrol
quercetin
curcumin
pterostilben
shown
antibacteri
properti
su
et
al
taylor
et
al
hwang
lim
et
al
zhou
et
al
could
also
interest
work
provid
first
vitro
demonstr
resveratrol
act
arb
potenti
colistin
activ
collect
colr
gramneg
pathogen
cover
wide
panel
speci
colistin
resist
mechan
limit
studi
synerg
resveratrol
colistin
test
colr
strain
p
aeruginosa
time
studi
avail
collect
potenti
exploit
featur
vivo
could
depend
resveratrol
concentr
achiev
vivo
differ
bodi
site
number
preclin
clinic
studi
previous
investig
resveratrol
administ
oral
et
al
intraven
et
al
inhal
varricchio
et
al
current
knowledg
resveratrol
pharmacokinet
human
remain
limit
given
oral
resveratrol
absorb
readili
metabol
lead
rather
low
bioavail
wall
et
al
boocock
et
al
et
al
nonabsorb
fraction
transform
compon
gut
microbiota
et
al
sever
resveratrolderiv
metabolit
identifi
human
anim
follow
oral
parenter
administr
includ
tran
andor
ci
form
mono
diglucuronid
mono
disulf
sulfoglucuronid
dihydroresveratrol
metabol
undergo
renal
fecal
excret
wall
et
al
boocock
et
al
et
al
consid
activ
specif
circul
resveratrol
metabolit
still
debat
concentr
unchang
resveratrol
human
urin
feac
plasma
still
clearli
determin
use
colistinresveratrol
combin
select
digest
decontamin
treatment
urinari
system
infect
would
deserv
investig
promis
set
exploit
synerg
resveratrol
colistin
would
respiratori
tract
infect
administr
inhal
formul
resveratrol
might
overcom
issu
relat
low
bioavail
metabol
compound
resveratrol
also
administ
nebul
human
varricchio
et
al
potenti
efficaci
colistinresveratrol
inhal
formul
could
deserv
attent
especi
case
chronic
lung
colon
difficulttotreat
gramneg
cystic
fibrosi
chronic
obstruct
pulmonari
diseas
bronchiectasi
relat
cystic
fibrosi
present
result
repres
proof
principl
studi
aim
evalu
potenti
role
resveratrol
colistin
arb
vitro
eg
biofilm
suscept
test
vivo
model
eg
select
decontamin
digest
tract
author
declar
research
conduct
absenc
commerci
financi
relationship
could
constru
potenti
conflict
interest
review
mb
handl
editor
declar
share
affili
